Cargando…
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells
The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancer-initiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells....
Autores principales: | Giordani, Giorgia, Barraco, Marilena, Giangrande, Angela, Martinelli, Giovanni, Guadagnuolo, Viviana, Simonetti, Giorgia, Perini, Giovanni, Bernardoni, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342419/ https://www.ncbi.nlm.nih.gov/pubmed/27486815 http://dx.doi.org/10.18632/oncotarget.10879 |
Ejemplares similares
-
Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019) -
Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
por: Minami, Yosuke, et al.
Publicado: (2017) -
Simultaneous Measurement of Smoothened Entry Into and Exit From the Primary Cilium
por: Kim, Jynho, et al.
Publicado: (2014) -
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018) -
A20 deficiency in multipotent progenitors perturbs quiescence of hematopoietic stem cells
por: Nakagawa, Masahiro Marshall, et al.
Publicado: (2018)